Investigational Drug Information for Raltitrexed

What is the development status for investigational drug Raltitrexed?

Raltitrexed is an investigational drug.

There have been 51 clinical trials for Raltitrexed. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1^st 2017.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Carcinoma, and Neoplasm Metastasis. The leading clinical trial sponsors are Fudan University, Jiangsu Cancer Institute & Hospital, and National Cancer Institute (NCI).

There is one US patent protecting this investigational drug and seventeen international patents.

Summary for Raltitrexed

US Patents	1,053
International Patents	17,012
US Patent Applications	2,142
WIPO Patent Applications	0
Japanese Patent Applications	4,150
Clinical Trial Progress	Phase 3 (2017-09-01)
Vendors	64

Recent Clinical Trials for Raltitrexed

Title	Sponsor	Phase
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial	Zhujiang Hospital	Phase 3
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial	Zhujiang Hospital	Phase 3
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients.	Anshan Tumor Hospital	Phase 1/Phase 2

See all Raltitrexed clinical trials

Clinical Trial Summary for Raltitrexed

Top disease conditions for Raltitrexed

Top clinical trial sponsors for Raltitrexed

See all Raltitrexed clinical trials

US Patents for Raltitrexed

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Raltitrexed		Heat shock protein 70 (hsp-70) receptor ligands	Duke University (Durham, NC)
Raltitrexed		Compounds and their methods of use	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Raltitrexed		Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus	Seattle Genetics, Inc. (Bothell, WA)
Raltitrexed		Method of diagnosing and treating cancer using B-catenin splice variants	The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)
Raltitrexed		Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers	Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)
Raltitrexed		Use of inhibitors of Bruton'S tyrosine kinase (Btk)	Pharmacyclics LLC (Sunnyvale, CA)
Raltitrexed		Use of inhibitors of Bruton's tyrosine kinase (Btk)	Pharmacyclics LLC (Sunnyvale, CA)

International Patents for Raltitrexed

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Raltitrexed	World Intellectual Property Organization (WIPO)	WO2015148714	2034-03-25
Raltitrexed	Australia	AU2015231053	2034-03-21
Raltitrexed	Brazil	BR112016021620	2034-03-21
Raltitrexed	Canada	CA2943339	2034-03-21
Raltitrexed	China	CN106231900	2034-03-21
Raltitrexed	Eurasian Patent Organization	EA201691896	2034-03-21
Raltitrexed	European Patent Office	EP3119199	2034-03-21